Introduction
============

Severe infections in ICU patients remain a major challenge in modern medicine. The prevalence of severe infections such as sepsis or septic shock in ICU patients ranges from 20 to 80% with high mortality rates of 20 to 50% \[[@B1]-[@B5]\]. Consequently, there is a substantial need for optimizing antimicrobial therapy. Key elements for the treatment of infections include an adequate antimicrobial therapy with an early initiation and with sufficiently high drug concentration levels \[[@B6]-[@B10]\]. Furthermore, sufficiently high drug concentrations are required to limit the development of antimicrobial resistance \[[@B11]\].

About 50% of bloodstream infections in critically ill patients are caused by Gram-positive bacteria \[[@B12],[@B13]\]. A major part of these Gram-positive infections are represented by multidrug-resistant strains (for example, methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE)), which are particularly frequent in ICUs \[[@B12]-[@B17]\]. Linezolid has good *in vitro* and *in vivo* activity against these organisms and is an important antibiotic for the treatment of infections in critically ill patients \[[@B9],[@B16],[@B18]-[@B22]\]. The volume of distribution in adults of this hydrophilic antibiotic approximates to the total body water content of 40 to 60 L \[[@B23]\]. The plasma elimination half-life is mostly reported to be between 3.1 and 4.9 h with a clearance rate between 6.4 and 14.8 L/h \[[@B23]\]. Linezolid is metabolized by liver enzymes to two major inactive metabolites, an aminoethoxyacetic acid and a hydroxyethyl glycine, which are excreted predominantly - together with the parent substance - in urine \[[@B24],[@B25]\]. Because of its intrinsic chemico-physical and pharmacokinetic characteristics, it is assumed that adequate serum linezolid concentrations will be achieved most of the time when using the recommended dose of 600 mg every 12 hours and that therapeutic drug monitoring (TDM) might not be necessary \[[@B26],[@B27]\]. This assumption is based on reports showing adequate linezolid concentrations in healthy volunteers or non-critically ill patients \[[@B27]-[@B29]\]. According to the manufacturer, no dose adjustment of linezolid is necessary in the case of renal or liver impairment. Consequently, expert panels recommend standardized doses of 600 mg linezolid twice a day also for patients with severe infections such as sepsis or septic shock \[[@B30]\]. However, 10 to 30% of critically ill patients receiving linezolid have treatment failure despite isolation of Gram-positive organisms sensitive to linezolid \[[@B16],[@B31],[@B32]\]. Of these, 15 to 30% of patients suffer furthermore from adverse effects such as elevated liver enzymes, gastrointestinal disturbances or hematological toxicity \[[@B32]-[@B34]\]. The rate of therapy failure and adverse effects may be in part explained by a high variability of linezolid serum concentrations in critically ill patients.

Though there are have been few studies evaluating blood levels and pharmacokinetic parameters of linezolid in critically ill patients \[[@B26],[@B35]-[@B41]\], it is still very difficult for physicians to decide if therapeutic levels are reached after standard dosing with linezolid when treating critically ill patients. The studies to date have found variable results with regard to linezolid blood levels. A substantial number demonstrated that inadequate levels occur \[[@B36],[@B37],[@B39],[@B41]\] whereas others concluded that standard doses are mostly sufficient \[[@B35],[@B38]\]. Low numbers of study patients, the lack of use of compartment models, and the retrospective design of most studies leave inconclusive information about this topic within the existing literature. Moreover, there are only preliminary data for linezolid blood levels in specific subgroups of ICU patients, such as critically ill patients on continuous renal replacement therapy (CRRT), those on extracorporeal lung assist (ECLA) and patients who have undergone organ transplantation \[[@B41],[@B42]\]. Indeed, most of these studies excluded particular patient groups, therefore, do not represent the full spectrum of different patients in ICUs. We therefore designed a prospective observational study to analyze the variability of linezolid serum concentrations in relation to preliminary target concentration ranges in a heterogeneous group of critically ill patients with suspected infections. The primary aim of the study was to evaluate whether linezolid serum concentrations in different critically ill patients were within the defined therapeutic range.

Materials and methods
=====================

Patients
--------

The study population originated from medical-surgical critically ill patients hospitalized in two ICUs within the Department of Anesthesiology, University Hospital of Munich between March and November 2013. Patients were eligible for inclusion if they had a severe infection (confirmed or suspected by clinical assessment) and were treated with linezolid intravenously by short-duration infusions according to the clinic guidelines, and in accordance with the German Paul-Ehrlich-Society and the guidelines of the Infectious Disease Society of America \[[@B30],[@B43]\]. Patients were only excluded if they were under the age of 18 years, if their planned hospitalization was less than 4 days, or if the first linezolid administration was given more than 48 h before study enrollment. Written informed consent was obtained from all patients or their legal representatives.

Study design
------------

The monocentric, prospective observational study was performed at the University Hospital of Munich. The study protocol (ClinicalTrials.gov, NCT01793012) was approved by the Institutional Review Board of the Medical Faculty of the Ludwig-Maximilians-University (registration number 428-12) and carried out according to the principles of the Declaration of Helsinki. Enrolled patients (n = 30) received 600 mg linezolid twice a day by short-duration infusion (15 to 60 minutes). Day 1 of the study was defined as that day on which the first linezolid trough level (C~min~) was determined (see Additional file [1](#S1){ref-type="supplementary-material"}). This was directly before the second or third linezolid administration in all patients except patients 2 and 27, for whom the study start was directly before the fifth and fourth linezolid administration, respectively. Serum samples from the arterial line for antibiotic determination were collected at multiple time points before (C~min~), during, and after the two linezolid administrations on day 1; and before, during, and after one of the two linezolid administrations on days 2, 3 and 4 (in total 26 to 43 samples per patient). The exact time of blood sampling was recorded by the medical staff. Samples were immediately sent to the Institute of Laboratory Medicine, University Hospital of Munich, centrifuged (3,000 g, 10 minutes) and aliquoted into 2-ml polypropylene tubes (Eppendorf, Hamburg, Germany). Serum aliquots were stored within one hour after blood sampling at -80°C.

Determination of clinical and laboratory parameters
---------------------------------------------------

Clinical patient data and diagnosis in the ICU were recorded. Sepsis was defined according to the Society of Critical Care Medicine/European Society of Intensive Care Medicine (SCCM/ESICM) Consensus Conference Committee \[[@B10]\]. The severity of the patient's clinical condition was characterized using the acute physiology and chronic health evaluation (APACHE) II score. To assess renal function, creatinine concentrations in both serum and 24-h urine samples were determined using an enzymatic photometric test on an automated chemistry analyzer (Model AU5822: Beckmann Coulter, Brea, CA, USA). Creatinine clearance (CL~crea~) was calculated using the formula:

$${CL}_{crea} = \left( {C_{urine}*V_{urine}} \right):\left( {C_{serum}*{time}} \right),$$

where C~urine~ is the creatinine concentration in urine, V~urine~ is the urine volume, and C~serum~ is the serum creatinine concentration.

Determination of linezolid concentrations
-----------------------------------------

Serum linezolid concentrations were determined using a previously described liquid chromatography tandem mass spectrometry (LC-MS/MS) method \[[@B44]\]. Briefly, sample preparation was based on protein precipitation and on-line solid phase extraction with two-dimensional liquid chromatography and column switching. Three-fold deuterated linezolid was used as the internal standard. Control samples were used from both a commercial provider and from in-house production. Validation revealed good analytical performance showing inaccuracy \<6% and imprecision \<7.3% (coefficient of variation) for all quality control samples. The lower limit of quantification was 0.13 mg/L. The method was found to be robust over the course of the study.

Pharmacokinetic analysis
------------------------

We analyzed linezolid plasma concentrations with a compartmental pharmacokinetic model based on nonlinear mixed-effects modeling. For model estimation we used the NONMEM 7.2® program (Icon Development Solutions, Hanover, MD, USA) with the FOCE-I estimation algorithm. The aim of the pharmacokinetic analysis was to determine individual concentration time courses. We assumed that the population parameters were log-normally distributed. The individual post-hoc concentration predictions obtained from NONMEM were used to predict the time course of linezolid plasma concentrations and to calculate the area under the concentration time curve over 24 h (AUC~24~)-values. Model selection was based on the NONMEM objective function, goodness-of-fit plots, and median absolute performance errors as described by Varvel *et al*. \[[@B45]\]. For graphical analysis we used PLTTools 5.0 PLTsoft, San Francisco, CA USA \[[@B46]\]. Linezolid plasma concentrations were calculated for each patient based on individual pharmacokinetic parameters in 10-minute steps.

Assessment of target concentration ranges
-----------------------------------------

The thresholds for potential therapeutic efficacy were defined as C~min~ \>2 mg/L and/or AUC~24~ \> 200 mg\*h/L. The rationale behind these two thresholds was the findings of Rayner *et al*., showing a higher therapeutic success in seriously ill patients when linezolid exceeds the minimum inhibitory concentration (MIC) over the entire dosing interval or when AUC~24~/MIC-values are higher than 80 to 120 \[[@B31]\]. We defined the MIC as the concentration that inhibits the growth of 90% of important relevant infectious pathogens (MIC~90~) (particularly *S. aureus* and Enterococcus species) \[[@B47],[@B48]\] and therefore, we set the threshold of potential therapeutic efficacy of C~min~ at 2 mg/L. As in Rayner *et al*., we set the AUC~24~/MIC~90~ value at 100, corresponding to a threshold for potential therapeutic efficacy of AUC~24~-values of 200 mg\*h/L. The threshold for potential therapeutic toxicity was defined as trough levels \>10 mg/L or AUC~24~ values \>400 mg\*h/L according to the literature \[[@B23],[@B26],[@B34]\].

Statistics
----------

The AUC~24~ was calculated by means of the trapezoidal rule using concentration values as predicted by the pharmacokinetic model (individual post-hoc concentration time course). Patients were divided into three groups in relation to the defined target concentration ranges based on their C~min~- and AUC~24~-values. Non-continuous parameters were expressed as percentages and numbers, and compared by means of the Chi-square test. Continuous parameters were expressed as median values and ranges, and compared by the Jonckheere-Terpstra test. A *P*-value below 0.05 was considered statistically significant. All calculations were performed using SAS (version 9.3, SAS Institute Inc., Cary, NC, USA).

Results
=======

Twenty male and ten female patients with a median age of 57 years (range, 28 to 84 years) and a median body mass index (BMI) of 25.5 kg/m^2^ (range, 16 to 35 kg/m^2^) were included. The most frequent causes of sepsis were pneumonia and peritonitis (Table  [1](#T1){ref-type="table"}). Ten patients were lung-transplant, and five were liver-transplant recipients. Patients had high variability in APACHE II scores (range 9 to 37, median 27.5). Of the 25 patients who were not on CRRT, 5 had a reduced creatinine clearance of \<50 ml/minute. Five patients were being treated with CRRT and seven patients were treated with ECLA. Detailed parameters of the corresponding CRRT and ECLA systems are shown in Additional files [2](#S2){ref-type="supplementary-material"} and [3](#S3){ref-type="supplementary-material"}.

###### 

Characteristics of the study population

  **Patient number**    **APACHE II score**   **Mean creatinine clearance (ml/minute)**^**a**^   **CRRT (+/-)**   **ECLA (+/-)**   **Organ transplantation**^**b**^  **Clinical condition**
  -------------------- --------------------- -------------------------------------------------- ---------------- ---------------- ---------------------------------- ------------------------
  1                             20                                   89                                \-               \+                       Lung                Septic pneumonia
  2                             12                                  129                                \-               \-                        \-                 ARDS
  3                             20                                   21                                \-               \-                        \-                 Septic peritonitis
  4                             28                                  114                                \-               \-                        \-                 Septic pleural empyema
  5                             23                                   97                                \-               \+                        \-                 ARDS
  6                             33                                   72                                \-               \+                        \-                 Septic pneumonia
  7                              9                                  117                                \-               \-                       Lung                Septic pneumonia
  8                             28                                  119                                \-               \-                       Lung                Septic pneumonia
  9                             28                                   \-                                \+               \-                      Liver                Septic peritonitis
  10                            29                                   94                                \-               \-                        \-                 Septic pneumonia
  11                            33                                   35                                \-               \-                       Lung                Septic pneumonia
  12                            31                                  102                                \-               \+                        \-                 Septic pneumonia
  13                            14                                  127                                \-               \-                        \-                 Septic pneumonia
  14                            14                                   69                                \-               \-                       Lung                Septic pneumonia
  15                            32                                   42                                \-               \-                        \-                 Septic endocarditis
  16                            19                                   76                                \-               \+                        \-                 Septic pneumonia
  17                            35                                   \-                                \+               \-                      Liver                Septic peritonitis
  18                            21                                   33                                \-               \-                       Lung                Septic pneumonia
  19                            27                                   55                                \-               \-                       Lung                Septic pneumonia
  20                            17                                   64                                \-               \-                       Lung                Septic pleural empyema
  21                            30                                   68                                \-               \-                        \-                 Septic pneumonia
  22                            23                                   \-                                \+               \-                      Liver                Septic peritonitis
  23                            14                                   85                                \-               \-                      Liver                Septic peritonitis
  24                            24                                   \-                                \+               \-                      Liver                Septic peritonitis
  25                            37                                   74                                \-               \-                       Lung                Septic pneumonia
  26                            25                                   83                                \-               \+                       Lung                Septic pneumonia
  27                            28                                   \-                                \+               \-                        \-                 Septic peritonitis
  28                            34                                  163                                \-               \+                        \-                 Septic pneumonia
  29                            32                                  126                                \-               \-                        \-                 ARDS
  30                            29                                   37                                \-               \-                        \-                 Septic peritonitis
  Median                       27.5                                  83                                                                                               
  (range)                    (9 to 37)                          (21 to 163)                                                                                           

^a^Mean value of the 4 study days; ^b^within the last 28 days. APACHE II, acute physiology and chronic health evaluation II score; CRRT, continuous renal replacement therapy; ECLA, extracorporeal lung assist; ARDS, acute respiratory distress syndrome.

Linezolid plasma concentrations were best described by a two-compartment model with an individual (post-hoc) median prediction error of 1% and a median absolute prediction error of 13%. The parameter estimates (standard error) of the population model were: volume of distribution of the first compartment = 19.3 (3.9) L, volume of distribution of the second compartment = 26.4 (3.8) L, elimination clearance = 8.3 (0.9) L/h and inter-compartmental clearance = 56.0 (19.3) L/h.

Figure  [1](#F1){ref-type="fig"} shows the concentration time curves of serum linezolid for each patient. A high inter-patient variability was observed. The high inter-patient variability could be quantified when AUC~24~-values ranged from 50.1 to 453.9 mg\*h/L (median 143.3 mg\*h/L) (Table  [2](#T2){ref-type="table"}). The high inter-patient variability was also observed for single C~min~-values (range \>100-fold, from \<0.13 to 14.49 mg/L, median 2.06 mg/L) (Table  [2](#T2){ref-type="table"}). To obtain further information about the usefulness of c~min~-values for TDM, C~min~ values were correlated with corresponding AUC~24~ values giving an *r*^2^ value of 0.79 (Additional file [4](#S4){ref-type="supplementary-material"}).

![**Serum concentration profiles of the 30 study patients.** Serum concentrations over the course of 4 days, as measured by liquid chromatography tandem mass spectrometry are shown.](cc13984-1){#F1}

###### 

Linezolid pharmacokinetic parameters following intravenous administration of 600 mg twice daily in critically ill ICU patients

  **Patient number**    **AUC**~**24**~**(mg\*h/L)**^**a**^   **C**~**min**~**(mg/L)**^**b**^
  -------------------- ------------------------------------- ---------------------------------
  1                                    99.1                                0.67
  2                                    50.1                              \<0.13^c^
  3                                    258.2                               3.35
  4                                    118.3                               1.89
  5                                    82.3                                0.46
  6                                    213.7                               3.15
  7                                    206.3                               3.59
  8                                    138.9                               1.17
  9                                    453.9                               13.75
  10                                   165.3                               3.26
  11                                   105.3                               0.43
  12                                   224.7                               4.13
  13                                   67.6                                0.14
  14                                   266.9                               2.31
  15                                   80.8                                0.70
  16                                   101.7                               0.18
  17                                   442.0                               14.49
  18                                   325.6                               2.75
  19                                   217.8                               3.48
  20                                   94.8                               \<0.13
  21                                   122.0                               1.03
  22                                   144.6                               3.70
  23                                   141.8                               2.22
  24                                   250.8                               8.18
  25                                   157.1                               1.45
  26                                   50.8                               \<0.13
  27                                   165.1                               4.22
  28                                   106.2                               0.17
  29                                   86.5                                0.45
  30                                   244.1                               5.86
  Median                               143.3                               2.06
  Range                            50.1 to 453.9                      \<0.13 to 14.49

^a^As determined by the NONMEM system, values from the start of the third administration of linezolid over 24 h; ^b^as analyzed by liquid chromatography tandem mass spectrometry, values obtained directly before the fourth administration of linezolid if not indicated otherwise;

^c^value obtained directly before the fifth administration of linezolid. AUC~24~, concentration time curve over 24 h; C~min~, linezolid trough level.

In addition to the inter-patient variability, high intra-patient variability of C~min~ values was also observed. Nine of thirty patients had maximum C~min~ values, more than 5-fold higher than the minimum C~min~ values (range of maximum/minimum C~min~ values 1 to 36) (Figure  [1](#F1){ref-type="fig"}; see also Additional file [5](#S5){ref-type="supplementary-material"}). The C~min~ of most patients did not change in a consistent pattern over the 4 days of the study; only in patients 3, 14, 18 and 25 did we observe an increase, and in patient 4 a decrease of C~min~ values over time (Figure  [1](#F1){ref-type="fig"}).

Optimal pharmacodynamic exposure over 24 h with AUC~24~ values between 200 and 400 mg\*h/L and at a single time point with C~min~ values between 2 and 10 mg/L was observed in 30% and 43% of the patients, respectively (Table  [3](#T3){ref-type="table"}, Figure  [1](#F1){ref-type="fig"}). Regarding these AUC~24~ and C~min~ values, 63% and 50% of the study patients had linezolid concentrations below the lower limit of the corresponding target concentration range, respectively, and 7% had linezolid concentrations above the target concentration range. Moreover, only 17% of the patients continuously attained optimal C~min~ values between 2 and 10 mg/L over 4 days (see Additional file [5](#S5){ref-type="supplementary-material"}).

###### 

Distribution of patients in relation to the target range of linezolid

                                           **Number (percentage) of linezolid patients**                                        
  --------------------------------------- ----------------------------------------------- -------- -------- --------- --------- --------
  Total patients, n =30                                       19 (63)                     9 (30)   2 (7)     15 (50)  13 (43)   2 (7)
  Male patients, n = 20^c^                                    13 (65)                     5 (25)   2 (10)    11 (55)  7 (35)    2 (10)
  Female patients, n = 10                                     6 (60)                      4 (40)             4 (40)   6 (60)     
  On CRRT, n = 5^d^                                           2 (40)                      1 (20)   2 (40)             3 (60)    2 (40)
  Not on CRRT, n = 25                                         17 (68)                     8 (32)             15 (60)  10 (40)    
  On ECLA, n = 7^c^                                           5 (71)                      2 (29)             5 (71)   2 (29)     
  Not on ECLA, n = 23                                         14 (61)                     7 (30)   2 (9)     10 (43)  11 (48)   2 (9)
  After liver transplantation, n = 5^f^                       2 (40)                      1 (20)   2 (40)             3 (60)    2 (40)
  After lung transplantation, n = 10^c^                       6 (60)                      4 (40)             6 (60)   4 (40)     
  No transplantation, n = 15                                  11 (73)                     4 (27)             9 (60)   6 (40)     

^a^As determined by the NONMEM system, values from the start of the third administration of linezolid; ^b^as determined by liquid chromatography tandem mass spectrometry, values obtained directly before the fourth administration of linezolid; ^c^no significantly different values in comparison to the corresponding patient group; ^d^significantly higher values in patients on CRRT than in those not on CRRT (*P* \<0.01); ^f^significantly higher values in patients with liver transplantation than in non-liver-transplant patients (*P* \<0.05). AUC~24~, concentration time curve over 24 h; C~min~, linezolid trough level; CRRT, continuous renal replacement therapy; ECLA, extracorporeal lung assist.

Patients on CRRT had significantly higher C~min~ values and AUC~24~ values than patients without CRRT (*P* = 0.005 for AUC~24~ and *P* = 0.001 for C~min~) (Table  [3](#T3){ref-type="table"}). Similarly, patients who had undergone liver transplantation had significantly higher AUC~24~ and C~min~ values than in non- (liver and lung) transplant patients (*P* = 0.036 for AUC~24~ and *P* = 0.012 for C~min~). Other characteristics such as gender, lung transplantation and therapy with ECLA did not have any significant influence on AUC~24~ or C~min~ values. Variability of linezolid levels was high in patient groups on CRRT and ECLA, and in the liver and lung transplantation groups, with each group showing a substantial proportion (≥40%) outside the target concentration range. The distributions of continuous parameters in relation to linezolid target ranges are shown in Table  [4](#T4){ref-type="table"}. A trend towards higher linezolid serum levels was observed in patients with reduced creatinine clearance, although these changes were not significant (*P* = 0.102 for C~min~ and *P* = 0.051 for AUC~24~) (Table  [4](#T4){ref-type="table"}, Additional file [6](#S6){ref-type="supplementary-material"}). Other continuous parameters such as age, BMI, and APACHE-II score did not have any significant influence on AUC~24~ or C~min~ values.

###### 

Distributions of continuous parameters in relation to linezolid target ranges

                                              **Median and range of patients**                                                 
  ------------------------------------------ ---------------------------------- ----------- ---------- ----------- ----------- ----------
  Mean creatinine clearance (mL/minute)^c^                                                                                     
   median                                                    89                     62                     89          70           
   range                                                 35 to 163               21 to 117              35 to 163   21 to 117       
   (number of patients)                                    \(17\)                  \(8\)                 \(15\)      \(10\)         
  APACHE II score                                                                                                              
   median                                                    28                     24          32         28          24          32
   range                                                  12 to 37                9 to 33    28 to 35   12 to 37     9 to 33    28 to 35
   (number of patients)                                    \(19\)                  \(9\)      \(2\)      \(15\)      \(13\)      \(2\)
  Age (years)                                                                                                                  
   median                                                    53                     59          56         57          57          56
   range                                                  28 to 77               34 to 84    50 to 61   28 to 77    29 to 84    50 to 61
   (number of patients)                                    \(19\)                  \(9\)      \(2\)      \(15\)      \(13\)      \(2\)
  Body mass index (kg/m^2^)                                                                                                    
   median                                                    24                     19          21         22          23          21
   range                                                  13 to 32               17 to 26    19 to 23   13 to 32    17 to 28    19 to 23
   (number of patients)                                    \(19\)                  \(9\)      \(2\)      \(15\)      \(13\)      \(2\)

^a^As determined by the NONMEM system, values from the start of the third administration of linezolid; ^b^as determined by liquid chromatography tandem mass spectrometry, values obtained directly before the fourth administration of linezolid; ^c^mean value of the 4 study days. AUC~24~, concentration time curve over 24 h; C~min~, linezolid trough level; APACHE II, acute physiology and chronic health evaluation II.

Discussion
==========

This study shows that the recommended standard dosing of linezolid leads to subtherapeutic linezolid plasma concentrations in about every second critically ill patient. Furthermore, a high variability of linezolid levels was observed in the study population with a majority (57 to 70%) detected outside the target ranges. Although there were insufficient levels in the majority of patients, inappropriate high levels occurred in a small number of patients. Finally, this variability of linezolid levels was not only observed between the different patients, but also within individual patients over the course of 4 days.

Our findings are in line with other studies also observing very low AUC~24~ or C~min~ values with the majority being insufficient \[[@B37],[@B39],[@B41]\]. In contrast to some other studies \[[@B37],[@B39]\], we used two different approaches to define the lower threshold of the target range. First, we used AUC~24~/MIC in concordance with other studies \[[@B26],[@B35],[@B36],[@B38],[@B40],[@B41]\], which was shown to be the best parameter to predict efficacy \[[@B31]\]. When we used this approach 63% of our study patients had insufficient linezolid serum levels. Second, we used C~min~ values as a further lower threshold of the target concentration range, as time above the MIC over the entire dosing interval also correlates with efficacy \[[@B31]\]. This value was set at 2 mg/L in accordance with MIC~90~ values of relevant causative pathogens \[[@B47],[@B48]\] as had been done in other studies \[[@B26],[@B37],[@B39]\]. Different efficacy thresholds might be used in environments where MIC~90~ values of relevant pathogens differ from 2 mg/L. Indeed, linezolid serum concentrations during infection should reach sufficient levels for most causative pathogens to ensure efficacy. This might be particularly important, as the identity of most causative pathogens is unknown in the early course of severe infection.

Furthermore, we showed that there is a high variability of linezolid AUC~24~ and C~min~ values with C~min~ values differing more than 100-fold between the different study patients and more than 30-fold within individual patients. This is in line with some recent studies also describing high variability of C~min~ values differing more than 50-fold between different patients \[[@B26],[@B34],[@B41]\]. In fact, the majority of linezolid concentrations in our study was outside the defined linezolid target concentration ranges, supporting the concept of TDM. We set the upper threshold of the target concentration range for C~min~ values at 10 mg/L. This was done in accordance with other studies, because higher concentrations have been shown to be associated with drug-related toxicity \[[@B23],[@B26],[@B34]\], whereas Pea *at al*. showed that in long-term treatment with linezolid an upper threshold of the target concentration range of 7 mg/L should be favored \[[@B49]\]. Indeed, in the study of Pea *et al*., all patients with C~min~ values \>10 mg/L of linezolid had substantial platelet reduction (\>30%) during long-term linezolid treatment, whereas no patient had these adverse effects with C~min~ values \<4 mg/L. Despite the rather high upper threshold used in our study, 7% of the patients had linezolid concentrations above the target range. The fact that for critically ill patients, the two parameters AUC~24~/MIC \>80 to 120 and time above MIC over the entire dosing interval strongly correlated with treatment efficacy \[[@B31]\], and that elevated linezolid concentrations correlated with adverse effects \[[@B23],[@B34]\], show that both AUC~24~ and C~min~ values correlate with efficacy and toxicity. This strongly supports the concept of linezolid target concentration ranges in terms of TDM. The good linear relationship between C~min~ and AUC~24~ values described by Pea *et al*. \[[@B26]\] was confirmed in our study (*r*^2^ = 0.79). C~min~ might therefore be a useful parameter for TDM of linezolid in clinical practice. As a high variation of C~min~ values within individual patients was observed in this study, we would recommend repetitive determinations of linezolid C~min~ values during infection treatment.

Finally, the linezolid serum concentrations in different critically ill patients, such as those on CRRT or ECLA, and patients who had undergone liver or lung transplantation, were evaluated. Only a few studies have evaluated the pharmacokinetics of linezolid in critically ill patients on CRRT \[[@B50]-[@B53]\], thereby using different CRRT systems such as continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemofiltration (CVVH). Linezolid concentrations were partly subtherapeutic and partly within the potential therapeutic range, however, a comparison of linezolid levels in patients not on CRRT was not performed. In our study, linezolid concentrations were tested in patients with CVVHDF and CVVHD. In comparison to the other study patients, significantly higher linezolid levels were observed in patients on CRRT. However, it should be noted that four of the five patients on CRRT were liver transplant recipients and that higher levels of linezolid have been reported in patients after liver transplantation \[[@B41]\]. About 50% of the parent substance linezolid is metabolized by liver enzymes to two major inactive metabolites and are excreted predominantly - together with linezolid - in urine \[[@B25]\]. Higher levels of linezolid in patients after liver transplantations might therefore be due to alterations in the activity of liver enzymes after ischemia/reperfusion \[[@B41]\]. Higher numbers of patients on CRRT and those after liver transplantations with simultaneous evaluation of the liver function, as well as of linezolid and its inactive metabolites in urine will be necessary to definitely understand the impact of CRRT and liver transplantations on linezolid concentrations in critically ill patients. Furthermore, we evaluated linezolid levels in patients after lung transplantation and patients on ECLA, and no significant differences (in the setting used in our study) in comparison to the whole study population were observed. Admittedly, the majority of the linezolid levels were also insufficient in these patients. This is in line with the reported low linezolid levels in three critically ill patients on extracorporeal membrane oxygenation-systems (specific ECLA system) and three critically ill patients after lung transplantation \[[@B42],[@B50]\], which are the only available data on these patients.

The results of this study suggest that the limited availability of linezolid quantification methods in clinical laboratories might pose a serious problem for the antimicrobial therapy of ICU patients. The reason for the limited availability of such methods is in particular the lack of cost-efficient commercially available linezolid quantification tests. Only a few laboratories use custom-made linezolid quantification methods such as high performance liquid chromatography with UV-detection (HPLC-UV) or LC-MS/MS. Development and routine use of these custom-made methods require a high level of human resources, professional specialization and high-technology equipment, which can often only be provided by large or specialized laboratories. The availability of commercial quantification tests (for example, based on HPLC-UV or immunoassay methods) of a therapeutic substance applied in life-threatening conditions might therefore be of particular impact.

The present study considered a number of aspects which have only partially been covered in previous work: (a) we investigated numerous critically ill patients from the whole intensive care spectrum, including patients who had undergone lung and liver transplantation and during CRRT and ECLA; (b) we analyzed a large number of linezolid plasma samples. This allowed description of individual concentration time courses by pharmacokinetic modeling with a small median prediction error of 1% and a small median absolute prediction error of 13%; (c) finally, this study used a highly accurate method for linezolid quantification \[[@B44]\]. All other studies measuring linezolid concentrations in critically ill patients used HPLC-UV \[[@B26],[@B35]-[@B41]\], which may be prone to interference, especially in critically ill patients with extended co-medication. In contrast, we used an LC-MS/MS method, thereby, for the first time, using isotope dilution internal standardization. As target analytes and internal standards are very similar in their physico-chemical properties, variances of individual samples impacting the ionization are compensated almost completely, realizing the highest attainable level of reliability \[[@B54]\]. Furthermore, the use of control samples from both a commercial provider and from in-house production additionally ensures the accuracy of the method. Indeed, there were only minimal undulations in the concentration-time curves of linezolid in individual patients (Figure  [1](#F1){ref-type="fig"}), showing that the study-protocol, including blood sampling and analytical method, was accurately performed.

The high variability of linezolid levels found in our study, with a substantial proportion at insufficient low levels, might contribute to the observed high mortality rate and severity of infection in ICU patients. Furthermore, high variability of linezolid levels may also lead to the development of resistance and drug-related toxicity. As early and effective antimicrobial therapy has a substantial effect on bacterial eradication and patient survival \[[@B6],[@B31]\], optimal individual dosing of antibiotics is of particular importance. Given the fact that the most common cause of death in the ICU in medically advanced nations is severe infection \[[@B55]\] and because of worldwide intentions to reduce morbidity and mortality from sepsis \[[@B10]\], we believe that there is great importance in optimizing individual antimicrobial dosing with the aid of TDM.

Conclusions
===========

We found high variability in linezolid serum concentrations with mostly insufficient low levels in critically ill patients. We therefore suggest general TDM of linezolid in critically ill patients during linezolid therapy. However, future studies will have to investigate whether application of TDM can definitely improve linezolid-dosing protocols and infection-related patient outcome.

Key messages
============

• High variability of linezolid serum concentrations after standard linezolid dosing in 30 different critically ill patients with suspected infections were observed.

• We observed potentially subtherapeutic levels in the majority of different patients.

• Potentially toxic levels were observed in a minority of different patients.

• Our data suggests that therapeutic drug monitoring might be helpful for adequate dosing of linezolid in critically ill patients.
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APACHE: acute physiology and chronic health evaluation; AUC~24~: concentration time curve over 24 h; BMI: body mass index; C~min~: linezolid trough level; CRRT: continuous renal replacement therapy; CVVH: continuous venovenous hemofiltration; CVVHD: Continuous venovenous hemodialysis; CVVHDF: continuous venovenous hemodiafiltration; ECLA: extracorporeal lung assist; HPLC-UV: high performance liquid chromatography with UV-detection; LC-MS/MS: liquid chromatography tandem mass spectrometry; MIC: minimal inhibitory concentration; MRSA: methicillin-resistant *Staphylococcus aureus*; SCCM/ESICM: Society of Critical Care Medicine/European Society of Intensive Care Medicine; TDM: therapeutic drug monitoring; VRE: vancomycin-resistant enterococci.
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###### Additional file 1

**Figure showing study protocol of blood sampling for linezolid determination.**^a^Two to three linezolid infusions before study start with the exception of patients 2 and 27, for whom the study start was directly before the fifth and fourth linezolid administration, respectively: ^b^26 to 43 samples per patient.
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###### Additional file 2

Table showing parameters of the continuous renal replacement therapy systems used for each patient in this study.
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###### Additional file 3

Table showing parameters of the extracorporeal lung-assist systems used for each patient in this study.
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###### Additional file 4

**Figure showing correlation of linezolid trough level (C**~**min**~**) values and concentration time curve over 24 h (AUC**~**24**~**) values of linezolid.** Shown are values for AUC~24~ as determined by the NONMEM system from the beginning of the third administration of linezolid, and C~min~ as determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) directly before the fourth administration of linezolid.
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###### Additional file 5

**Figure demonstrating the high variability (inter-patient and intrapatient) of linezolid trough levels (C**~**min**~**) over the course of the study for each patient.**

###### 

Click here for file

###### Additional file 6

**Table showing concentration time curve over 24 h (AUC**~**24**~**) and linezolid trough level (C**~**min**~**) values of patients from the lowest and highest quartile of covariates.**
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